SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETH Sits 'In The Middle Of Nothing' Heading Into The Back Half Of A Red October

Cryptocurrency

Long-term investors might see the current trading range for Ethereum as an accumulation opportunity, analysts said.

ETH Price Faces Fresh Risk As Tom Lee Flags Korea Margin Calls – Warns Of A Potential Crypto Spillover

The Korea Exchange suspended program sell orders for five minutes after KOSPI 200 futures fell 5.08%, triggering a sell-side sidecar for the first time since Aug. 19


Ethereum Logs Smallest Year-To-Date Loss Since January As Rally Runs On Thin Leverage

Analyst Ted Pillows sees $2,800 as a key level for Ethereum, saying a weekly close above it could confirm further upside.

Tom Lee Says ‘Stay Tuned’ As Bitmine Nears 5% Ethereum Goal, Hints At What’s Next

Equity

Tom Lee-backed Bitmine now holds 4.9% of the supply of all the Ethereum in circulation.


Ethereum Hits 7-Month High, Marks First Close Above $2,750 Since Late January

Tom Lee said easing oil prices and more stable bond yields have reduced recent market pressure, while bearish sentiment and oversold conditions could provide fuel for a sharp stock rally in September.

XRP Gets Second-Largest Weight In Grayscale's Bitcoin-Free Advisor Portfolio

Grayscale’s Bitcoin-free Next Gen portfolio gives XRP the second-largest allocation at 26.11%, behind Ethereum.

Ethereum On Track To Snap Its Longest Quarterly Losing Streak On Record

Ethereum is up about 58% in the third quarter, putting it on track to snap its first-ever three-quarter losing streak.


Jordi Visser Warns Betting Against Treasury Intervention Is ‘A Very Dangerous Game,’ Favors Bitcoin Over Equities

Visser referred to Bitcoin as the “S&P 500 of the crypto world,” and saw it as a significant store of value in the digital economy.


Arthur Hayes Calls Ethereum Foundation 'A Bunch Of Jokers' In A Blunt Take But Is Bullish On ETH

Hayes believes a move above $3,000 could trigger reflexive buying and potentially send Ethereum toward the $5,000 level.


Arthur Hayes Says AI Spending Boom Is ‘Lehman, Not Apple’ – Sees Bitcoin Eventually Hitting $1M

AI is pulling liquidity, and concerns over Strategy are weighing on sentiment, Arthur Hayes said, which could push Bitcoin down before pushing it up.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$ETH.X" data-symbol-id="ETH.X" href="https://stocktwits.com/symbol/ETH.X" target="_blank">Ethereum</a> is down almost 10% so far this month, on course for a third straight red October.</li><li>Crypto analyst Michaël van de Poppe said ETH remains directionless in the near term but could turn bullish if it breaks key resistance levels.</li><li>Analyst Ted Pillows warned that a weekly close below $2,450 could trigger another correction.</li></ul>As Ethereum (ETH) slid nearly 10% this month and headed for its third straight red October, crypto analyst Michaël van de Poppe said on Sunday the token was "in the middle of nothing.”The MNFund founder&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/CryptoMichNL/status/2111785614542794920">said</a> that Ethereum still showed "a potential bullish divergence," but added that it "needs to break resistances in order to be actually approved." Until then, he sees the direction as open. "At this point, it's in the middle of nothing, and we could have both ends," he wrote. He was more upbeat on the longer view, saying that "on the higher timeframe," the "dips are generally for buying."<figure class="image"><a class="st-link-external" href="https://x.com/CryptoMichNL/status/2111785614542794920" target="_blank" rel="noopener noreferrer nofollow"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_10_18_at_11_03_30_AM_664cec9cdc.png" alt="Screenshot 2026-10-18 at 11.03.30 AM.png" width="1048" height="682"></a><figcaption>Source: @CryptoMichNL/x</figcaption></figure><h2 class="st-heading-2">Ethereum’s Next Correction</h2>Crypto analyst Ted Pillows was more cautious in the near term. "$ETH is looking weak here," he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/TedPillows/status/2111751566621393260">w</a><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/TedPillows/status/2111751566621393260">rote</a> on X. Pillows said a weekly close below $2,450 looked likely and could lead to "one more correction." His chart marked about $2,357 as the first support level, with resistance near $2,802.<figure class="image"><a class="st-link-external" href="https://x.com/TedPillows/status/2111751566621393260" target="_blank" rel="noopener noreferrer nofollow"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_10_18_at_11_05_42_AM_f8ba979226.png" alt="Screenshot 2026-10-18 at 11.05.42 AM.png" width="1062" height="506"></a><figcaption>Source: @TedPillows/x</figcaption></figure>Like van de Poppe, he saw value for patient buyers. "But if you're thinking long-term, Ethereum is in a good accumulation zone," Pillows said.<h2 class="st-heading-2">Potential Third Red October In A Row</h2>October has rarely been kind to Ethereum, with a median return of just 0.08%, according to CoinGlass&nbsp;data. The token is down 9.91% so far this month, after falling 7.02% last October and 3.4% in October 2024.&nbsp;A red finish would mark Ethereum's first three consecutive months losing streak since it started trading.&nbsp;This year's slide also followed a strong summer, when the token gained 32.53% in August and 8.77% in September. Even after this month's drop, Ethereum remains roughly 30% above its July close, based on CoinGlass monthly figures.&nbsp;<h2 class="st-heading-2">Losing Ground To Bitcoin</h2><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261018_101719257_25273d18c4.png" alt="koyfin_20261018_101719257.png" width="3600" height="1860"><figcaption>Ethereum and Bitcoin ratio 0.82%. Source: Koyfin</figcaption></figure>Ethereum is falling behind Bitcoin, with the ETH/BTC pair sliding to near 0.0294 BTC, down 0.82% on the chart. While this ratio has bounced back from its lows in June and rallied through the summer, it topped out in September and has drifted lower in October, meaning that Ethereum has been underperforming Bitcoin recently.<a href="https://stocktwits.com/coins/ethereum">Ethereum’s price</a> was trading around $2,386, down over 1% in the past 24 hours. On Stocktwits, retail sentiment around ETH remained in the ‘extremely bearish’ zone over the past day.&nbsp;<a href="https://stocktwits.com/coins/bitcoin">Bitcoin’s price</a> was trading at $81,240, up 0.1% in the past 24 hours. On Stocktwits, retail sentiment around BTC dropped to ‘extremely bearish’ from the ‘bearish’ zone, over the past day.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/wall-street-veteran-jordi-visser-ties-bitcoin-s-next-leg-up-to-big-tech-earnings/cZxN0JJRBtY">Wall Street Veteran Jordi Visser Ties Bitcoin's Next Leg Up To Big Tech Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration of the digital Cryptocurrency, Ethereum and Bitcoin, are seen on September 13 2018 in Hong Kong, Hong Kong. (Photo Illustration by Yu Chun Christopher Wong/S3studio/Getty Images)

As Ethereum (ETH) slid nearly 10% this month and headed for its third straight red October, crypto analyst Michaël van de Poppe said on Sunday the token was "in the middle of nothing.”

Grayscale Ethereum Mini Trust

iShares Ethereum Trust ETF

Grayscale Ethereum Trust

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$21.29
Prev Close	$22.28
Open	$21.23
Dividend Yield	N/A
50-Day Moving Average	$23.92
Beta	2.15
Avg. Volume	3.27M
PE Ratio	N/A

52-Week High	$35.21
52-Week Low	$14.53
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

ETH Fundamentals